Seer (SEER) Cash & Equivalents (2020 - 2026)
Seer (SEER) posted quarterly Cash & Equivalents of $47.3 million for Q1 2026, down 9.78% year-over-year from $52.4 million in Q1 2025, and little changed quarter-over-quarter from $47.3 million in Q4 2025.
Seer (SEER) Cash & Equivalents (2020 - 2026) Analysis & Trends
Seer's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 9.78% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (down 9.78% YoY), while the FY2025 annual figure was $47.3 million, up 16.03% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $47.3 million, roughly flat from $47.3 million in the prior quarter.
- The five-year high for Cash & Equivalents was $225.3 million in Q1 2022, with the low at $31.9 million in Q2 2024.
- The 5-year median for Cash & Equivalents is $47.3 million (2026), against an average of $58.5 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 79.46% in 2022, then advanced 25.4% in 2024.
- Seer's Cash & Equivalents stood at $53.2 million in 2022, then plunged by 38.92% to $32.5 million in 2023, then rose by 25.4% to $40.8 million in 2024, then rose by 16.03% to $47.3 million in 2025, then increased by 0.07% to $47.3 million in 2026.
- Business Quant data shows SEER's Cash & Equivalents at $47.3 million in Q1 2026, $47.3 million in Q4 2025, and $45.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | 26.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.08 Mn |
| Mar 31, 2026 | 47.32 Mn |
| Dec 31, 2025 | 47.29 Mn |
| Sep 30, 2025 | 44.97 Mn |
| Jun 30, 2025 | 37.93 Mn |
| Mar 31, 2025 | 52.45 Mn |
| Dec 31, 2024 | 40.75 Mn |
| Sep 30, 2024 | 37.62 Mn |
| Jun 30, 2024 | 31.95 Mn |
| Mar 31, 2024 | 54.40 Mn |
| Dec 31, 2023 | 32.50 Mn |
| Sep 30, 2023 | 36.40 Mn |
| Jun 30, 2023 | 56.40 Mn |
| Mar 31, 2023 | 48.39 Mn |
| Dec 31, 2022 | 53.21 Mn |
| Sep 30, 2022 | 68.07 Mn |
| Jun 30, 2022 | 79.02 Mn |
| Mar 31, 2022 | 225.33 Mn |
| Dec 31, 2021 | 232.81 Mn |
| Sep 30, 2021 | 331.40 Mn |